CLINICAL PAYMENT AND CODING POLICY

In the event of a conflict between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. Plan documents include but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions and other coverage documents.

In the event of a conflict between a Clinical Payment and Coding Policy and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern.

Providers are responsible for accurately, completely, and legibly documenting the services performed including any preoperative workup. The billing office is expected to submit claims for services rendered using valid codes from the Health Insurance Portability and Accountability Act (HIPAA) approved code sets. Claims should be coded appropriately according to industry-standard coding guidelines including, but not limited to: Uniform Billing (UB) Editor, American Medical Association (AMA), Current Procedural Terminology (CPT®), CPT® Assistant, Healthcare Common Procedure Coding System (HCPCS), National Drug Codes (NDC), Diagnosis Related Group (DRG) guidelines, Centers for Medicare and Medicaid Services (CMS) National Correct Coding Initiative (CCI) Policy Manual, CCI table edits and other CMS guidelines. Claims are subject to the code edit protocols for services/procedures billed.

Preventive Services Policy

Policy Number: CPCP006

Version 1.0

Enterprise Clinical Payment and Coding Policy Committee Approval Date: 09/26/2019

Effective Date: 10/01/2019

Description

Section 2713 of the Affordable Care Act mandates that private health plans provide coverage of preventive services issued by the following agencies: The United States Preventive Services Task Force (USPSTF), the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC), and the Health Resources and Service Administration (HRSA) with respect to women’s guidelines and guidelines for infants, children and adolescents. These services are available at no cost-share when obtained by a member covered under a non-grandfathered plan. This applies to members belonging to an individual, small group, large group and self-insured plans. There is no copay, deductible or coinsurance, even if the individual or family deductible or out-of-pocket maximum has not been met as long as the member utilizes a provider in the plan’s network.
The Patient Protection and Affordable Care Act of 2010 does not mandate that preventive services be covered at no member cost-share when obtained out-of-network. Members that obtain preventive services out of their network will be subject to copay, deductible and coinsurance. Grandfathered plans are plans that have been in existence before March 23, 2010, and are exempt from the requirement of providing preventive services at no member cost-share. Grandfathered plans have the opportunity to elect providing coverage of preventive services at no member cost-share but are not required to do so.

The following acronyms have been utilized throughout this reimbursement policy
ACIP: Advisory Committee on Immunization Practices
CDC: Centers for Disease Control and Prevention
FDA: United States Food and Drug Administration
HRSA: Health Resources and Services Administration
PPACA: Patient Protection and Affordable Care Act of 2010
USPSTF: United States Preventive Services Task Force

The United States Preventive Services Task Force (USPSTF) applies a letter grade for each of the recommendations that are released. The grade definitions for USPSTF recommendations released after July 2012 are as follows https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions

Following the recommendation of the United States Preventive Services Task Force coverage of Grade “A” and “B” recommendations is provided at no member cost-share for members with a non-grandfathered health plan. The United States Preventive Services Task Force published recommendations can be found at https://www.uspreventiveservicestaskforce.org/BrowseRec/Index

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>The USPSTF recommends the service. There is high certainty that the net benefit is substantial.</td>
</tr>
<tr>
<td>B</td>
<td>The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.</td>
</tr>
<tr>
<td>C</td>
<td>The USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small.</td>
</tr>
<tr>
<td>D</td>
<td>The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.</td>
</tr>
<tr>
<td>I</td>
<td>The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality or conflicting and the balance of benefits and harms cannot be determined.</td>
</tr>
</tbody>
</table>
The Advisory Committee on Immunization Practices (ACIP) publishes recommendations on the safe utilization of vaccines. ACIP’s recommendations include immunization schedules for children and adolescents as well as adults which can be found at https://www.cdc.gov/vaccines/schedules/hcp/index.html. Travel Immunizations such as, but not limited to, Japanese Encephalitis, Typhoid, Yellow Fever, and Small Pox are excluded from Preventive Service coverage. Other excluded vaccinations include Anthrax, Bacille Calmette Guerin for Tuberculosis (BCG), and Rabies which are not required by the Patient Protection and Affordable Care Act of 2010. Immunizations should be administered in accordance with the ACIP Recommended Child and Adult Immunization Schedules or in accordance with state law or regulations.

The Health Resources and Services Administration (HRSA) releases Women’s Preventive Services guidelines that are aimed at improving women’s health by recommending certain preventive services that should be obtained in the clinical setting. HRSA’s list of recommendations can be obtained at https://www.hrsa.gov/womensguidelines2016/index.html.

The Health Resources and Services Administration (HRSA) endorses preventive guidelines established by the American Academy of Pediatrics for the health and well-being of infants, children and adolescents. These recommendations are referred to as Bright Futures and the comprehensive list of Bright Future’s recommendations can be found at https://www.aap.org/en-us/Documents/practicet_periodicity_AllVisits.pdf.

**Reimbursement Information:**

Preventive care or preventive medicine refers to measures or services taken to promote health and early detection/prevention of disease(s) and injuries rather than treating them and/or curing them. Preventive care may include examinations and screening tests tailored to an individual’s age, health and family history.

Certain preventive care services may be considered eligible for coverage under the member’s benefit plan as required by the Affordable Care Act and/or an applicable state mandate. In general, these services include but are not limited to screenings, immunizations and other types of care as recommended by the United States Federal Government.

These services are not subject to the application of cost-sharing such as copayments, co-insurance or deductibles when they are considered eligible for coverage and are provided by a network provider. In order for preventive claims to process at the preventive level with no member cost share, the claim must include a preventive diagnosis code, a preventive procedure code, meet medical policy review criteria and fall within the guidelines issued by the USPSTF, ACIP, HRSA or Bright Futures.
Health care providers (facilities, physicians and other health care professionals) are expected to exercise independent medical judgement in providing care to patients. This Preventive Services Reimbursement policy is not intended to impact care decisions or medical practice. Providers are responsible for accurately, completely, and legibly documenting the services performed. The billing office is expected to submit claims for services rendered using valid codes from HIPAA-approved code sets.

The following grid provides a list of the recommendations released by the USPSTF, ACIP, HRSA or Bright Futures along with the corresponding procedure codes and diagnosis codes deemed to be preventive.

**USPSTF Recommendations:**

<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal Aortic Aneurysm Screening</td>
<td>76706</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>USPSTF “B” Recommendation June 2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The USPSTF recommends one-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men ages 65 to 75 years who have ever smoked.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormal Blood Glucose and Type 2 Diabetes Mellitus Screening</td>
<td>82947, 82948, 82950, 82951, 83036, 82952</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>USPSTF “B” Recommendation October 2015</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The USPSTF recommends screening for abnormal blood glucose as part of cardiovascular risk assessment in adults aged 40 to 70 years who are overweight or obese. Clinicians should offer or refer patients with abnormal blood glucose to intensive behavioral counseling interventions to promote a healthful diet and physical activity.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions</td>
<td>99385, 99386, 99387, 99395, 99396, 99397, 99408, 99409, G0396, G0397, G0442, G0443</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>USPSTF “B” Recommendation November 2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Service:</td>
<td>Procedure Code(s):</td>
<td>Additional Reimbursement Criteria:</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>The USPSTF recommends screening for unhealthy alcohol use in primary care settings for adults 18 years or older, including pregnant women, and providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce unhealthy alcohol use.</td>
<td></td>
<td>For details about pharmacy benefit coverage, contact the number on the patient’s BCBS member card. A patient’s pharmacy benefit may be managed by a company other than BCBS. Prescription required Coverage includes 81 mg dosage for generics</td>
</tr>
</tbody>
</table>
| **Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer Preventive Medication**  
USPSTF “B” Recommendation April 2016  
The USPSTF recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. | 81007, 87086, 87088 | Payable with a Pregnancy Diagnosis |
| **Asymptomatic Bacteriuria in Adults Screening**  
USPSTF “A” Recommendation July 2008  
The USPSTF recommends screening for asymptomatic bacteriuria with urine culture for pregnant women at 12 to 16 weeks’ gestation or at their first prenatal visit, if later. |                    |                                                                                                     |
| **BRCA-Related Cancer Risk Assessment, Genetic Testing**  
USPSTF “B” Recommendation August 2019  
The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool. | 81212, 81215, 81216, 81217, 81162, 81163, 81164, 81165, 81166, 81167, 96040, 99385, 99386, 99387, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 60463, 50265 | These services are subject to Medical Policy and prior authorization may be required Procedure codes 81212, 81215-81217, and 81162-81167 are reimbursable as preventive when submitted with one of the following primary diagnosis codes: Z80.3, Z80.41, Z85.3, Z85.43 |
## CLINICAL PAYMENT AND CODING POLICY

<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA-Related Cancer Risk Assessment, Genetic Testing (cont.)</td>
<td></td>
<td>Procedure code 96040 is reimbursable as preventive when submitted with one of the following primary diagnosis codes: Z80.3 or Z80.41. All other procedure codes for BRCA are payable with a diagnosis in Diagnosis List 1.</td>
</tr>
<tr>
<td>Breast Cancer Medications for Risk Reduction</td>
<td></td>
<td>For details about pharmacy benefit coverage, contact the number on the patient’s BCBS member card. A patient’s pharmacy benefit may be managed by a company other than BCBS. Prescription required. Generic drugs Tamoxifen and Raloxifene are reimbursable at the preventive level for ages 35 and over.</td>
</tr>
<tr>
<td>Breast Cancer Screening</td>
<td>77061, 77062, 77063, 77067</td>
<td>Payable with a diagnosis code in Diagnosis List 1.</td>
</tr>
<tr>
<td>Breastfeeding Primary Care Interventions</td>
<td>99401, 99402, 99403, 99404, 99411, 99412, A4281, A4282, A4283, A4284, A4285, A4286, E0602, E0603, E0604, S9443</td>
<td>Electric breast pumps limited to one per benefit period. Hospital Grade breast pumps are limited to rental only. Additional reimbursement information available within the “Breastfeeding Equipment and Supplies” recommendation.</td>
</tr>
<tr>
<td>Cervical Cancer Screening</td>
<td>99385, 99386, 99387, 99395, 99396, 99397</td>
<td>Payable with a diagnosis code in Diagnosis List 1.</td>
</tr>
</tbody>
</table>
### CLINICAL PAYMENT AND CODING POLICY

<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting). Refer also to HRSA’s ‘Cervical Cancer Screening’ recommendation</td>
<td>G0101, 88141, 88142, 88143, 88147, 88148, 88150, 88152, 88153, 88155, 88164, 88165, 88166, 88167, 88174, 88175, G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091, 87623, 87624, 87625, S0610, S0612, 0500T, 0096U</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
</tbody>
</table>
| **Chlamydia Screening**  
USPSTF “B” Recommendations September 2014  
The USPSTF recommends screening for chlamydia in sexually active women age 24 years and younger and in older women who are at increased risk for infection. | 86631, 86632, 87110, 87270, 87320, 87490, 87491, 87492, 87801, 87810 | Payable with a diagnosis in Diagnosis List 1 |
| **Colorectal Cancer Screening**  
USPSTF “A” Recommendation June 2016  
The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years. The risks and benefits of different screening methods vary. | 82270, 82274, G0328, 44388, 44389, 44392, 44394, 44401, 44404, 45378, 45380, 45381, 45384, 45385, 45388, G0105, G0106, G0120, G0121, G0122, 45330, 45331, 45333, 45335, 45338, 45346, 74263, 88304, 88305, G0104, 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, S0285, 00812, 00813, 81528 | Certain colorectal cancer screening services may be subject to medical policy criteria and may require prior authorization  
Modifier 33 or PT may be applied  
Payable with a diagnosis in Diagnosis List 1  
In the instance that a polyp is removed during a preventive colonoscopy, the colonoscopy as well as the removal of the polyp and the labs and services related to the colonoscopy are reimbursable at the preventive level.  
Sedation procedure codes 99152, 99153, 99156, 99157 and G0500 will process at the preventive level |

---
## CLINICAL PAYMENT AND CODING POLICY

<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
</table>
| **Congenital Hypothyroidism Screening**  | 84443, 99381, S3620 | when billed with a diagnosis of Z12.11 or Z12.12  
Procedure code 74263 is reimbursable at the preventive level when billed with one of the following three diagnosis codes: Z00.00, Z12.11, Z12.12 |
| **Dental Caries in Children from Birth Through Age 5 Years Screening** | 99188 | Prescription required for both over-the-counter (OTC) and prescription medications |
| **Depression Screening Adults**               | 99385, 99386, 99387, 99395, 99396, 99397, 96160, 96161, G0444 | Payable with a diagnosis code in Diagnosis List 1 |
| **Depression in Children and Adolescents Screening** | 99384, 99385, 99394, 99395, 96127, G0444 | Payable with a diagnosis in Diagnosis List 1 |

**USPSTF “A” Recommendation March 2008**
The USPSTF recommends screening for congenital hypothyroidism in newborns.

**USPSTF “B” Recommendation May 2014**
The USPSTF recommends that primary care clinicians prescribe oral fluoride supplementation starting at age 6 months for children whose water supply is deficient in fluoride.

**USPSTF “B” Recommendation May 2014**
The USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.

**USPSTF “B” Recommendation January 2016**
The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment and appropriate follow-up.
### CLINICAL PAYMENT AND CODING POLICY

<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>USPSTF “B” Recommendation February 2016 The USPSTF recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment and appropriate follow-up. Refer also to Bright Futures ‘Depression Screening’ recommendation</td>
<td>97110, 97112, 97116, 97150, 97161, 97162, 97163, 97164, 97165, 97166, 97167, 97168, 97530</td>
<td>Effective 1/1/2019, Procedure code 96127 is only reimbursable at the preventive level when billed with a diagnosis of Z00.129, Z13.41, or Z13.42</td>
</tr>
<tr>
<td>Falls Prevention in Community Dwelling Older Adults: Interventions USPSTF “B” Recommendation April 2018 The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults aged 65 years or older who are at increased risk for falls.</td>
<td>97110, 97112, 97116, 97150, 97161, 97162, 97163, 97164, 97165, 97166, 97167, 97168, 97530</td>
<td>Prescription required Procedure codes 97110, 97112, 97116, 97150, 97161, 97162, 97163, 97164, 97165, 97166, 97167, 97168 and 97530 reimbursable with a diagnosis of Z91.81</td>
</tr>
<tr>
<td>Folic Acid for the Prevention of Neural Tube Defects: Preventive Medication USPSTF “A” Recommendation January 2017 The USPSTF recommends that all women who are planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic acid.</td>
<td>36415, 82947, 82948, 82950, 82951, 82952, 83036</td>
<td>Prescription required Over-the-counter (OTC) only</td>
</tr>
<tr>
<td>Gestational Diabetes Mellitus Screening USPSTF “B” Recommendation January 2014 The USPSTF recommends screening for gestational diabetes mellitus (GDM) in asymptomatic pregnant women after 24 weeks of gestation. Refer also to HRSA’s ‘Gestational Diabetes’ recommendation</td>
<td>36415, 82947, 82948, 82950, 82951, 82952, 83036</td>
<td>Payable with a pregnancy diagnosis</td>
</tr>
<tr>
<td>Gonorrhea Screening USPSTF “B” Recommendation September 2014</td>
<td>87801, 87590, 87591, 87592, 87850</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Service:</td>
<td>Procedure Code(s):</td>
<td>Additional Reimbursement Criteria:</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>The USPSTF recommends screening for gonorrhea in sexually active women</td>
<td>99385, 99386, 99387, 99395, 99396, 99397, G0438, G0439, G0446, S9452, S9470,</td>
<td>Payable with a pregnancy diagnosis or diagnosis in Diagnosis List 1</td>
</tr>
<tr>
<td>age 24 years and younger and in older women who are at increased risk</td>
<td>97802, 97803, 97804, G0270, G0271, 99078, 99401, 99402, 99403, 99404, 99411, 99412,</td>
<td></td>
</tr>
<tr>
<td>for infection.</td>
<td>G0473</td>
<td></td>
</tr>
<tr>
<td>**Healthful Diet and Physical Activity for Cardiovascular Disease</td>
<td>80055, 86706, 87340, 87341, 80074, 80076, G0499, 36415</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Prevention in Adults with Cardiovascular Risk Factors: Behavioral</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Counseling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>USPSTF “B” Recommendation August 2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The USPSTF recommends offering or referring adults who are overweight</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and obese and have additional cardiovascular disease (CVD) risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>factors to intensive behavioral counseling interventions to promote a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>healthful diet and physical activity for CVD prevention.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis B in Pregnant Women Screening</strong></td>
<td>80055, 86706, 87340, 87341, 80074, 80076, G0499, 36415</td>
<td>Payable with a pregnancy diagnosis or diagnosis in Diagnosis List 1</td>
</tr>
<tr>
<td>USPSTF “A” Recommendation July 2019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The USPSTF recommends screening for hepatitis B virus (HBV) infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>in pregnant women at their first prenatal visit.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis B Virus Infection Screening</strong></td>
<td>80055, 86706, 87340, 87341, 80074, 80076</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>USPSTF “B” Recommendation May 2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The USPSTF recommends screening for hepatitis B virus (HBV) infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>in persons at high risk for infection.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis C Screening</strong></td>
<td>86803, 86804, G0472</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>USPSTF “B” Recommendation June 2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The USPSTF recommends screening for hepatitis C virus (HCV) infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>in persons at high risk for infection.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The USPSTF also recommends offering 1-time screening for HCV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>infection to adults born between 1945 and 1965.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>High Blood Pressure in Adults Screening</strong></td>
<td>93784, 93786, 93788, 93790, 99385, 99386,</td>
<td>Procedure codes 93784, 93786, 93788, and 93790 are reimbursable at the preventive</td>
</tr>
<tr>
<td>USPSTF “A” Recommendation October 2015</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Service:</td>
<td>Procedure Code(s):</td>
<td>Additional Reimbursement Criteria:</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>The USPSTF recommends screening for high blood pressure in adults aged 18 years or older. The USPSTF recommends obtaining measurements outside of the clinical setting for diagnostic confirmation before starting treatment.</td>
<td>99387, 99395, 99396, 99397</td>
<td>level when billed with one of the following diagnosis codes: R03.0, R03.1, Z01.30, Z01.31</td>
</tr>
<tr>
<td>Human Immunodeficiency Virus (HIV) Infection Screening for Non-Pregnant Adolescents and Adults</td>
<td>87806, 87389, 87390, 87391, G0432, G0433, G0435</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>USPSTF “A” Recommendation June 2019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk should also be screened.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refer also to HRSA’s ‘HIV Screening and Counseling’ recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refer also to Bright Future’s ‘STI/HIV Screening’ recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Immunodeficiency Virus (HIV) Infection Screening for Pregnant Women</td>
<td>36415, 80081, 86689, 86701, 86702, 86703, 87389, 87390, 87391, 87806, G0432, G0433, G0435, G0475</td>
<td>Payable with a pregnancy diagnosis or diagnosis from Diagnosis List 1</td>
</tr>
<tr>
<td>USPSTF “A” Recommendation June 2019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The USPSTF recommends that clinicians screen all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refer also to HRSA’s ‘HIV Screening and Counseling’ recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refer also to Bright Future’s ‘STI/HIV Screening’ recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intimate Partner Violence, Elder Abuse and Abuse of Vulnerable Adults Screening</td>
<td>99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99384, 99385, 99386,99387, 99394, 99395, 99396, 99397,</td>
<td></td>
</tr>
<tr>
<td>Service:</td>
<td>Procedure Code(s):</td>
<td>Additional Reimbursement Criteria:</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>reproductive age and provide or refer women who screen positive to ongoing support services.</td>
<td>99401, 99402, 99403, 99404, 99411, 99412, S0610, S0612, S0613</td>
<td></td>
</tr>
<tr>
<td><strong>Latent Tuberculosis Infection Screening</strong>&lt;br&gt;USPSTF “B” Recommendation September 2016&lt;br&gt;The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk.</td>
<td>86480, 86481, 86580</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td><strong>Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality from Preeclampsia: Preventive Medication</strong>&lt;br&gt;USPSTF “B” Recommendation September 2014&lt;br&gt;The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia.</td>
<td></td>
<td>Prescription required&lt;br&gt;Coverage includes 81 mg dosage for generics&lt;br&gt;For details about pharmacy benefit coverage, contact the number on the patient’s BCBS member card. A patient’s pharmacy benefit may be managed by a company other than BCBS.</td>
</tr>
<tr>
<td><strong>Lung Cancer Screening</strong>&lt;br&gt;USPSTF “B” Recommendation December 2013&lt;br&gt;The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.</td>
<td>G0296, G0297</td>
<td>Subject to medical policy criteria and may require preauthorization&lt;br&gt;Procedure code G0297 is reimbursable at the preventive level if it meets medical policy criteria and is billed with one of the following diagnosis codes: F17.200, F17.201, F17.210, F17.211, F17.220, F17.221, F17.290, F17.291, Z12.2, Z87.891</td>
</tr>
<tr>
<td><strong>Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions</strong></td>
<td>97802, 97803, 97804, 99385, 99386, 99387, 99395, 99396, 99397,</td>
<td></td>
</tr>
<tr>
<td>Service:</td>
<td>Procedure Code(s):</td>
<td>Additional Reimbursement Criteria:</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td><strong>USPSTF “B” Recommendation September 2018</strong>&lt;br&gt;The USPSTF recommends that clinicians offer or refer adults with a body mass index (BMI) of 30 or higher (calculated as weight in kilograms divided by height in meters squared) to intensive, multicomponent behavioral interventions.</td>
<td>99401, 99402, 99403, 99404, 99411, 99412, 99078, G0447, G0473</td>
<td></td>
</tr>
<tr>
<td><strong>Obesity in Children and Adolescents Screening</strong>&lt;br&gt;USPSTF “B” Recommendation June 2017&lt;br&gt;The USPSTF recommends that clinicians screen for obesity in children and adolescents 6 years and older and offer them or refer them to comprehensive, intensive behavioral interventions to promote improvement in weight status.</td>
<td>97802, 97803, 99383, 99384, 99385, 99393, 99401, 99402, 99403, 99404, 99411, 99412, G0446, G0447, G0473</td>
<td></td>
</tr>
<tr>
<td><strong>Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum Preventive Medication</strong>&lt;br&gt;USPSTF “A” Recommendation January 2019&lt;br&gt;The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum.</td>
<td></td>
<td>When billed under inpatient medical</td>
</tr>
<tr>
<td><strong>Osteoporosis Screening</strong>&lt;br&gt;USPSTF “B” Recommendation June 2018&lt;br&gt;The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older. The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool.</td>
<td>76977, 77078, 77080, 77081, 78350, 78351, G0130, 0554T, 0555T, 0556T, 0557T</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Service:</td>
<td>Procedure Code</td>
<td>Additional Reimbursement Criteria:</td>
</tr>
<tr>
<td>---------</td>
<td>----------------</td>
<td>-----------------------------------</td>
</tr>
</tbody>
</table>
| **Perinatal Depression: Preventive Interventions**  
USPSTF “B” Recommendation February 2019  
The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions | 99385, 99385, 99387, 99395, 99396, 99397, 96160, 96161, G0444 | Payable with a diagnosis on Diagnosis List 1 |
| **Phenylketonuria in Newborns Screening**  
USPSTF “A” Recommendation March 2008  
The USPSTF recommends screening for phenylketonuria in newborns. | 84030, 99381, S3620 | Procedure codes 84030 and S3620 reimbursable at the preventive level for children 0-90 days old |
| **Preeclampsia Screening**  
USPSTF “B” Recommendation April 2017  
The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy. | 80055, 86850, 86870, 86900, 86901, 36415 | Preeclampsia screening is done through routine blood pressure measurements |
| **Rh(D) Incompatibility Screening**  
USPSTF “A” Recommendation February 2004  
The USPSTF strongly recommends Rh(D) blood typing and antibody testing for all pregnant women during their first visit for pregnancy-related care.  
USPSTF “B” Recommendation February 2004  
The USPSTF recommends repeated Rh(D) antibody testing for all unsensitized Rh(D)-negative women at 24 to 28 weeks' gestation, unless the biological father is known to be Rh(D)-negative. | 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, G0445 | Payable with a pregnancy diagnosis |
| **Sexually Transmitted Infections Behavioral Counseling**  
USPSTF “B” Recommendation September 2014  
The USPSTF recommends intensive | 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, G0445 |
<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>behavioral counseling for all sexually active adolescents and for adults who are at increased risk for sexually transmitted infections (STIs). <em>Refer also to HRSA’s ‘Sexually Transmitted Infections Counseling’ recommendation</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Sickle Cell Disease (Hemoglobinopathies) in Newborns Screening**  
USPSTF “A” Recommendation September 2007  
The USPSTF recommends screening for sickle cell disease in newborns. | 83020, 83021, 83030, 83033, 83051, 85004, 85013, 85014, 85018, 85025, 85027, 99381, G0306, G0307, S3620, S3850 | |
| **Skin Cancer Counseling**  
USPSTF “B” Recommendation March 2018  
The USPSTF recommends counseling young adults, adolescents, children, and parents of young children about minimizing exposure to ultraviolet (UV) radiation for persons aged 6 months to 24 years with fair skin types to reduce their risk of skin cancer. | There are no procedure codes specific to skin cancer counseling. | |
| **Statin Use for the Primary Prevention of Cardiovascular Disease in Adults Preventive Medication**  
USPSTF “B” Recommendation November 2016  
The USPSTF recommends that adults without a history of cardiovascular disease (CVD) (i.e., symptomatic coronary artery disease or ischemic stroke) use a low- to moderate-dose statin for the prevention of CVD events and mortality when all of the following criteria are met: 1) they are aged 40 to 75 years; 2) they have 1 or more CVD risk factors (i.e., dyslipidemia, diabetes, hypertension or smoking); and 3) they have a calculated 10-year risk of a cardiovascular event of 10% or greater. | 80061, 82465, 83700, 83718, 83719, 83721, 84478 | Prescription required  
Ages 40-75 only  
Lovastatin 20mg, 40mg  
Pravastatin 10mg, 20mg, 40mg, 80mg  
For details about pharmacy benefit coverage, contact the number on the patient’s BCBS member card. A patient’s pharmacy benefit may be managed by a company other than BCBS. |
<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identification of dyslipidemia and calculation of 10-year CVD event risk requires universal lipids screening in adults aged 40 to 75 years.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Syphilis Infection in Nonpregnant Adults and Adolescents Screening</strong>&lt;br&gt;USPSTF “A” Recommendation June 2016&lt;br&gt;The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection.</td>
<td>86592, 86780, 0065U</td>
<td>Payable with a diagnosis in Diagnosis List 1</td>
</tr>
<tr>
<td><strong>Syphilis Infection in Pregnant Women Screening</strong>&lt;br&gt;USPSTF “A” Recommendation September 2018&lt;br&gt;The USPSTF recommends early screening for syphilis infection in all pregnant women.</td>
<td>80055, 80081, 86592, 86593, 0065U, 36415</td>
<td>Payable with a pregnancy diagnosis or a diagnosis in Diagnosis List 1</td>
</tr>
<tr>
<td><strong>Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions</strong>&lt;br&gt;USPSTF “A” Recommendation September 2015&lt;br&gt;The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and U.S. Food and Drug Administration (FDA)–approved pharmacotherapy for cessation to adults who use tobacco.</td>
<td>99401, 99402, 99403, 99404, 99406, 99407, G9016, S9453</td>
<td>Two 90-day treatment regimens per benefit period. The 90-day treatments are at the discretion of the provider working with the member&lt;br&gt;Prescription required for all pharmacotherapy interventions&lt;br&gt;bupropion tan ER 150 mg tablets Chantix&lt;br&gt;Microtron Inhaler&lt;br&gt;Nicotrol NS&lt;br&gt;Nicotine Transdermal Kits&lt;br&gt;Generic gum and lozenges (nicotine polacrilex 2 mg, 4 mg)&lt;br&gt;For details about pharmacy benefit coverage, contact the number on the patient’s BCBS member card. A patient’s pharmacy benefit may be managed by a company other than BCBS.</td>
</tr>
</tbody>
</table>
## CLINICAL PAYMENT AND CODING POLICY

<table>
<thead>
<tr>
<th>Service: Tobacco Use in Children and Adolescents Primary Care Interventions</th>
<th>Procedure Code(s): 99401, 99402, 99403, 99404, 99406, 99407, G9016, S9453</th>
<th>Additional Reimbursement Criteria: Refer to Preventive Services Recommendation for Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>USPSTF “B” Recommendation August 2013 The USPSTF recommends that primary care clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Service: Vision Screening in Children</th>
<th>Procedure Code(s): 99172, 99173, 0333T</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>USPSTF “B” Recommendation September 2017 The USPSTF recommends vision screening at least once in all children aged 3 to 5 years to detect amblyopia or its risk factors.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Service: General Lab Panel</th>
<th>Procedure Code(s): 80050, 80053</th>
<th>Additional Reimbursement Criteria: Payable with a diagnosis on Diagnosis List 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>These lab codes could be multiple Preventive Services recommendations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### HRSA Recommendations:

<table>
<thead>
<tr>
<th>Service: Breast Cancer Screening for Women at Average Risk</th>
<th>Procedure Code(s): 77061, 77062, 77063, 77065, 77066, 77067, G0279</th>
<th>Additional Reimbursement Criteria: Payable with a diagnosis code in Diagnosis List 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRSA Recommendation December 2016 The Women’s Preventive Services Initiative recommends that average-risk women initiate mammography screening no earlier than age 40 and no later than age 50. Screening mammography should occur at least biennially and as frequently as annually. Screening should continue through at least age 74 and age alone should not be the basis to discontinue screening. These screening recommendations are for women at average risk of breast cancer. Women at increased risk should also undergo periodic mammography</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Service:</td>
<td>Procedure Code(s):</td>
<td>Additional Reimbursement Criteria:</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>Breastfeeding Services and Supplies</td>
<td>E0602, E0603, E0604, A4281, A4282, A4283, A4284, A4285, A4286, S9443, 99401, 99402, 99403, 99404, 99411, 99412, 99347, 99348, 99349, 99350</td>
<td>Electric breast pumps limited to one per benefit period. Hospital Grade breast pumps are limited to rental only. Additional reimbursement information available within the “Breastfeeding Equipment and Supplies” Coverage</td>
</tr>
<tr>
<td>Cervical Cancer Screening</td>
<td>99385, 99386, 99387, 99395, 99396, 99397, G0101, 88141, 88142, 88143, 88147, 88148, 88150, 88152, 88164, 88165, 88166, 88167, 88174, 88175, G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091, 87623, 87624, S0610, S0612</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Contraceptive Methods and Counseling</td>
<td>A4268, A4269, 57170, 74740, 96372, 11976</td>
<td>Contraception methods that require a prescription may be covered under the patient’s Service: Procedure Code(s):</td>
</tr>
<tr>
<td>Service:</td>
<td>Procedure Code(s):</td>
<td>Additional Reimbursement Criteria:</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>HRSA Recommendation December 2016</td>
<td>11981, 11982, 11983, 58300, 58301, A4261, A4264, A4266, S4981, S4989, J1050, J7297, J7298, J7300, J7301, J7303, J7304, J7306, J7307, 58600, 58605, 58611, 58615, 58661, 58565, 58670, 58671, 58340, J7296</td>
<td>medical or pharmacy benefit. For details about pharmacy benefit coverage for contraception, contact the number on the patient’s BCBS member card. A patient’s pharmacy benefit may be managed by a company other than BCBS. Visits pertaining to contraceptive counseling, initiation of contraceptive use, and follow-up care may also apply to procedure codes under HRSA’s ‘Well-Woman’ recommendation. Procedure code 58340 reimbursable at the preventive level only when accompanied with modifier 33 or one of the following diagnosis codes: Z30.2, Z30.40, Z30.42, Z30.49, Z98.51. Procedure codes 11981, 11982, and 11983 (are covered only when FDA approved contraceptive implant insertion or removal are performed) are reimbursable at the preventive level when billed with one of the following diagnosis codes: Z30.013, Z30.014, Z30.017, Z30.018, Z30.19, Z30.09, Z30.40, Z30.42, Z30.430, Z30.432, Z30.433, Z30.46, Z30.49, Z30.8, Z30.9. Procedure code 58661 reimbursable at the preventive level with a diagnosis of Z30.2. For the list of contraceptive methods that may be covered, visit your health plan website.</td>
</tr>
</tbody>
</table>
### CLINICAL PAYMENT AND CODING POLICY

<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
</table>
| **Diabetes Mellitus Screening after Pregnancy**  
  HRSA Recommendation December 2017  
The Women’s Preventive Services Initiative recommends women with a history of gestational diabetes mellitus (GDM) who are not currently pregnant and who have not been previously diagnosed with type 2 diabetes mellitus should be screened for diabetes mellitus. | 82947, 82948, 82950, 82951, 83036 | Payable with a diagnosis code in Diagnosis List 1 |
| **Gestational Diabetes**  
  HRSA Recommendation December 2016  
The Women’s Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening with a 50-g oral glucose challenge test (followed by a 3-hour 100-g oral glucose tolerance test if results on the initial oral glucose challenge test are abnormal) is preferred because of its high sensitivity and specificity. The Women’s Preventive Services Initiative suggests that women with risk factors for diabetes mellitus be screened for preexisting diabetes before 24 weeks of gestation—ideally at the first prenatal visit, based on current clinical best practices  
Refer also to USPSTF’s ‘Gestational Diabetes Mellitus Screening’ recommendation | 82947, 82948, 82950, 82951, 83036 | Payable with a pregnancy diagnosis |
| **Human Immune-Deficiency Virus Counseling & Screening**  
  HRSA Recommendation December 2016  
The Women’s Preventive Services Initiative recommends prevention education and risk assessment for human immunodeficiency virus (HIV) infection in adolescents and women at least annually throughout the life span. All women should be tested for HIV | 36415, 86689, 86701, 86702, 86703, 87389, 87390, 87391, 87806, G0432, G0433, G0435, G0475 | Payable when billed with a diagnosis in Diagnosis List 1 |
at least once during their lifetime. Additional screening should be based on risk, and screening annually or more often may be appropriate for adolescents and women with an increased risk of HIV infection. Screening for HIV is recommended for all pregnant women upon initiation of prenatal care with retesting during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.

Refer also to USPSTF’s ‘Human Immunodeficiency Virus (HIV) Infection Screening for Pregnant and Non-Pregnant Adolescents and Adults’ recommendation

Refer also to Bright Future’s ‘STI/HIV Screening’ recommendations

### Human Papillomavirus Testing (HPV)

**HRSA Recommendation August 2012**

HRSA recommends high-risk human papillomavirus DNA testing in women with normal cytology results. Screening should begin at 30 years of age and should occur no more frequently than every 3 years

<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Papillomavirus Testing (HPV)</td>
<td>87623, 87624, 87625, G0476, 0500T, 0096U</td>
<td>Payable with a diagnosis in Diagnosis List 1</td>
</tr>
</tbody>
</table>

### Interpersonal and Domestic Violence Screening

**HRSA Recommendation December 2016**

The Women’s Preventive Services Initiative recommends screening adolescents and women for interpersonal and domestic violence at least annually, and, when needed, providing or referring for initial intervention services. Interpersonal and domestic violence includes physical violence, sexual violence, stalking and psychological aggression (including coercion), reproductive coercion, neglect, and the threat of violence, abuse or both. Intervention services include but are

<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interpersonal and Domestic Violence Screening</td>
<td>99401, 99402, 99403, 99404, 99411, 99412, 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215</td>
</tr>
</tbody>
</table>
### CLINICAL PAYMENT AND CODING POLICY

<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>not limited to, counseling, education, harm reduction strategies, and referral to appropriate supportive services.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sexually Transmitted Infections Counseling</strong>&lt;br&gt;HRSA Recommendation December 2016&lt;br&gt;The Women’s Preventive Services Initiative recommends directed behavioral counseling by a health care provider or other appropriately trained individual for sexually active adolescent and adult women at an increased risk for sexually transmitted infections (STIs). The Women’s Preventive Services Initiative recommends that health care providers use a woman’s sexual history and risk factors to help identify those at an increased risk of STIs. Risk factors may include age younger than 25, a recent history of an STI, a new sex partner, multiple partners, a partner with concurrent partners, a partner with an STI, and a lack of or inconsistent condom use. For adolescents and women not identified as high risk, counseling to reduce the risk of STIs should be considered, as determined by clinical judgement.&lt;br&gt;Refer also to USPSTF’s ‘Sexually Transmitted Infections Behavioral Counseling’ recommendation</td>
<td>99401, 99402, 99403, 99404, 99411, 99412, 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, G0445</td>
<td></td>
</tr>
<tr>
<td><strong>Urinary Incontinence Screening</strong>&lt;br&gt;HRSA Recommendation December 2017&lt;br&gt;The Women’s Preventive Services Initiative recommends screening women for urinary incontinence annually. Screening should ideally assess whether women experience urinary incontinence and whether it impacts their activities and quality of life.</td>
<td>There are no procedure codes specific to this service. This service would be part of the preventive office visit.</td>
<td>Payable with a diagnosis in Diagnosis List 1</td>
</tr>
<tr>
<td><strong>Well-Woman Visits</strong>&lt;br&gt;HRSA Recommendation December 2016</td>
<td>99384, 99385, 99386, 99387, 99394, 99395,</td>
<td>Labs administered as part of a normal pregnancy reimbursable at</td>
</tr>
</tbody>
</table>

---

**Note:**
- Refer to USPSTF’s ‘Sexually Transmitted Infections Behavioral Counseling’ recommendation for more details.
- Labs administered as part of a normal pregnancy reimbursable at standard rates.
The Women’s Preventive Services Initiative recommends that women receive at least one preventive care visit per year beginning in adolescence and continuing across the life span to ensure that the recommended preventive services, including preconception, and many services necessary for prenatal and interconception care are obtained. The primary purpose of these visits should be the delivery and coordination of recommended preventive services as determined by age and risk factors.

ACIP Recommendations:

<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTaP Vaccine</td>
<td>90696, 90698, 90700, 90702, 90723</td>
<td>Payable at the preventive level for members between the ages of 9-45. Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Hepatitis A Vaccine</td>
<td>90632, 90633, 90634, 90636</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B Vaccine</td>
<td>90739, 90740, 90743, 90744, 90746, 90747, 90748</td>
<td></td>
</tr>
<tr>
<td>Haemophilus Influenzae Type B (Hib) Vaccine</td>
<td>90647, 90648</td>
<td></td>
</tr>
<tr>
<td>Human Papillomavirus Vaccine (HPV)</td>
<td>90649, 90650, 90651</td>
<td></td>
</tr>
<tr>
<td>Influenza Vaccine</td>
<td>90630, 90653, 90654, 90655, 90656, 90657, 90658, 90660, 90661, 90662, 90666, 90667, 90668, 90672, 90673, 90674, 90682, 90685, 90686, 90687, 90688, 90756, Q2034, 99396, 99397, G0101, G0438, G0439, 99078, 99401, 99402, 99403, 99404, 99411, 99412, 99408, 99409, G0396, G0442, G0443, G0444</td>
<td>the preventive level when billed with a pregnancy diagnosis</td>
</tr>
<tr>
<td>Service</td>
<td>Procedure Code(s):</td>
<td>Additional Reimbursement Criteria:</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-----------------------------------------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>Measles, Rubella, Congenital Rubella Syndrome and Mumps (MMR)</td>
<td>Q2035, Q2036, Q2037, Q2038, Q2039</td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella and Varicella (MMRV)</td>
<td>90707</td>
<td></td>
</tr>
<tr>
<td>Meningococcal Vaccine</td>
<td>90644, 90733, 90734, 90619, 90620, 90621</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal Vaccine</td>
<td>90670, 90732</td>
<td></td>
</tr>
<tr>
<td>Polio Vaccine</td>
<td>90713</td>
<td></td>
</tr>
<tr>
<td>Rotavirus Vaccine</td>
<td>90680, 90681</td>
<td></td>
</tr>
<tr>
<td>Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap/Td)</td>
<td>90714, 90715</td>
<td></td>
</tr>
<tr>
<td>Varicella Vaccine</td>
<td>90716</td>
<td></td>
</tr>
<tr>
<td>Zoster (Shingles) Vaccine</td>
<td>90736, 90750</td>
<td>Payable at the preventive level for members age 50 and older</td>
</tr>
<tr>
<td>Immunization Administration</td>
<td>90460, 90461, 90471, 90472, 90473, 90474, 90674, 90749</td>
<td></td>
</tr>
</tbody>
</table>

Bright Futures Recommendations:

<table>
<thead>
<tr>
<th>Service</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol Use and Drug Use Assessment</td>
<td>99408, 99409</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Bright Futures Recommendations:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol Use and Drug Use Assessment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bright Futures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bright Futures Recommends alcohol and drug use assessments for adolescents between the ages of 11 to 21 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical Dysplasia Screening</td>
<td>Q0091</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Service:</td>
<td>Procedure Code(s):</td>
<td>Additional Reimbursement Criteria:</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>--------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Bright Futures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommends cervical dysplasia screening for adolescents age 21 years of age</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Critical Congenital Heart Defect Screening</strong></td>
<td>94760</td>
<td></td>
</tr>
<tr>
<td>Bright Futures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommends screening for critical congenital heart disease using pulse oximetry for newborns after 24 hours of age, before discharge from the hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Depression Screening</strong></td>
<td>96110</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Bright Futures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommends depression screening for adolescents between the ages of 11 to 21 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refer also to USPSTF’s ‘Depression in Children and Adolescents Screening’ recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Developmental Screening / Autism Screening</strong></td>
<td>96110</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Bright Futures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommends developmental/autism screening for infants and young children between the ages of 9 months and 30 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dyslipidemia Screening</strong></td>
<td>80061, 82465, 83718, 84478</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Bright Futures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommends dyslipidemia screening for children and adolescents between the ages of 24 months and 21 years of age</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hearing Screening</strong></td>
<td>92558, 92586, 92567, 92551, V5008</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Bright Futures</td>
<td></td>
<td>Procedure code 92586 is for members under 32 days of age</td>
</tr>
<tr>
<td>Recommends hearing screenings for children and adolescents from birth through 21 years of age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Service:</td>
<td>Procedure Code(s):</td>
<td>Additional Reimbursement Criteria:</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>--------------------</td>
<td>-------------------------------------------------------------------</td>
</tr>
<tr>
<td>Hematocrit or Hemoglobin</td>
<td>36415, 36416, 85014, 85018</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Bright Futures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommends hematocrit or hemoglobin screening for children and adolescents between the ages of four months and 21 years of age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV Screening</td>
<td>87389, 87390, 87391, 87806, G0432, G0433, G0435</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Lead Screening</td>
<td>36415, 36416, 83655</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Bright Futures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommends screening children between the ages of six months and six years for lead</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal Depression Screening</td>
<td>99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, G0444</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Newborn Bilirubin</td>
<td>82247, 82248</td>
<td>Payable with a diagnosis in Diagnosis List 1</td>
</tr>
<tr>
<td>Newborn Blood Screening</td>
<td>G3620</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Oral Health</td>
<td>99211, 99212, 99188, 99381, 99382, 99383, 99384</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Bright Futures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommends oral health risk assessments beginning at six months of age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prenatal Visit</td>
<td>99401, 99402, 99403, 99404</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Preventive Medicine Services: New Patients</td>
<td>99381, 99382, 99383, 99384, 99385</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Preventive Medicine Services: Established Patients</td>
<td>99391, 99392, 99393, 99394, 99395</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>STI/HIV Screening</td>
<td>86631, 86632, 86701, 86703, 87081, 87110, 87210, 87270, 87320, 87490, 87491, 87590, 87591, 87800, 87801,</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Bright Futures</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### CLINICAL PAYMENT AND CODING POLICY

<table>
<thead>
<tr>
<th>Service:</th>
<th>Procedure Code(s):</th>
<th>Additional Reimbursement Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refer also to USPSTF’s ‘Human Immunodeficiency Virus (HIV) Infection Screening for Pregnant and Non-Pregnant Adolescents and Adults’ recommendations</td>
<td>87810, 87850, 36415</td>
<td></td>
</tr>
<tr>
<td>Refer also to HRSA’s ‘Sexually Transmitted Infections Counseling’ recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tuberculosis Testing</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bright Futures</td>
<td>86580, 99211</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Recommends tuberculosis testing if the risk assessment is positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vision Screening</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bright Futures</td>
<td>99173</td>
<td>Payable with a diagnosis code in Diagnosis List 1</td>
</tr>
<tr>
<td>Recommends vision screening for newborns through age 21 years</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Many of the services listed above may be performed for indications other than preventive care. In these situations, services may be covered by another provision of the individual’s benefit plan and subject to applicable cost-sharing.

**Diagnosis List 1**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Z00.00</td>
<td>Z00.01</td>
<td>Z00.110</td>
<td>Z00.111</td>
<td>Z00.121</td>
<td>Z00.129</td>
<td>Z00.08</td>
</tr>
<tr>
<td>Z01.10</td>
<td>Z01.411</td>
<td>Z01.419</td>
<td>Z02.83</td>
<td>Z11.1</td>
<td>Z11.3</td>
<td>Z11.4</td>
</tr>
<tr>
<td>Z11.51</td>
<td>Z11.7</td>
<td>Z12.11</td>
<td>Z12.12</td>
<td>Z12.2</td>
<td>Z12.31</td>
<td>Z12.39</td>
</tr>
<tr>
<td>Z30.018</td>
<td>Z30.019</td>
<td>Z30.02</td>
<td>Z30.09</td>
<td>Z30.40</td>
<td>Z30.41</td>
<td>Z30.42</td>
</tr>
<tr>
<td>Z30.49</td>
<td>Z30.8</td>
<td>Z30.9</td>
<td>Z32.2</td>
<td>Z71.41</td>
<td>Z71.51</td>
<td>Z71.6</td>
</tr>
<tr>
<td>Z71.7</td>
<td>Z71.82</td>
<td>Z71.83</td>
<td>Z86.32</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Breastfeeding Equipment & Supplies**

Non-grandfathered plans provide coverage of manual, electric, and hospital grade breast pumps along with breastfeeding supplies at the preventive level.
CLINICAL PAYMENT AND CODING POLICY

Manual breast pumps utilize procedure code E0602 and are available for purchase and covered at the preventive level when obtained In-Network, Out-of-Network or from Retail providers. Sales tax is excluded from retail purchases.

Electric breast pumps utilize procedure code E0603 and must be rented or purchased from an In-Network provider or a contracted durable medical equipment supplier. The models of breast pumps being provided at the preventive level are up to the individual provider’s discretion. If a member chooses to obtain an upgraded model, they may be balance billed the difference between the allowance of the standard model and the cost of the upgraded model. Members are allowed one electric breast pump per benefit period.

*Note: Retail providers such as Babies ‘R’ Us, Target, Walmart or online vendor are not licensed medical providers and therefore are considered Out-of-Network. Out-of-network coverage will follow the out-of-network benefit level for preventive services. This may include cost-sharing and sales tax is excluded.*

Hospital-grade breast pumps utilize procedure code E0604 and are only covered when rented In-Network or from an In-Network durable medical equipment supplier. Hospital-grade breast pump coverage is up to the purchase price of $1,000.00 or 12 months, whichever comes first. At the end of coverage, the unit must be returned to the durable medical equipment supplier. Members are allowed one breast pump per benefit period.

Breast pumps obtained from Out-of-Network providers are reimbursable at the Out of Network level.

The following breast pump supplies are reimbursable the preventive level. Some limitations and restrictions may apply based on the group coverage for preventive services.

- A4281- Tubing for a breast pump, replacement, spare membranes, replacements
- A4282- Adapter for a breast pump, replacement
- A4283- Cap for a breast pump bottle, replacement
- A4284- Breast shield and splash protector for use with a breast pump, replacement
- A4285- Polycarbonate bottle for use with a breast pump, replacement
- A4286- Locking ring for a breast pump, replacement

Differentiating Preventive Care versus Diagnostic Care

The following types of services are considered Preventive:

- Screenings intended to prevent illness or identify issues before symptoms are evident
- Counseling intervention as defined by a specific preventive recommendation
Examples of preventive services:

- A 60-year-old woman obtains her biennial mammogram to screen for breast cancer
- A patient who has been identified as having cardiovascular disease risk factors is referred for nutritional counseling
- A 50-year old patient obtains a colonoscopy to screen for colorectal cancer
- A 42-year-old patient goes to their doctor for their annual physical and receives a blood test to screen for abnormal blood glucose

The following types of services are considered Diagnostic:

- The diagnosis of existing symptoms or abnormalities
- Treatment for specific health conditions, ongoing care, or other tests to manage a health condition

Examples of diagnostic services:

- A 60-year-old woman obtains a mammogram after noticing a lump in her breast
- A patient diagnosed with diabetes is referred for nutritional counseling to manage their condition
- A patient goes to their doctor for their annual physical and receives a blood test to check iron and liver function, and a urinalysis is requested

Limitations and Exclusions

1. Services not reimbursable at the preventive level may be reimbursable under another portion of the medical plan.
2. Breastfeeding equipment and supplies not listed underneath the “Breastfeeding Equipment and Supplies” section. This includes, but is not limited to:
   a. Batteries
   b. Breastfeeding ointments, creams
   c. Breast milk storage supplies including bags, freezer packs, etc.
   d. Breast pump cleaning supplies
   e. Breast pump traveling cases
   f. Infant scales
   g. Nursing bras
   h. Nursing covers, scarfs
3. Immunizations that are not published in the Center for Disease Control’s Morbidity and Mortality Weekly Report (MMWR) and/or are not on the list of “Vaccines Licensed for Use in the United States” by the United States Food and Drug Administration (FDA).
4. Prescription coverage may vary depending on the terms and conditions of the plans. A prescription may be required for coverage under the pharmacy benefit. The plan may also require that the generic drug be tried first before the brand version. Age limits, restrictions and other requirements may apply. Members can verify their pharmacy benefits by calling the customer service number on the back of their ID card.
5. For OTC purchases, members will need to obtain a prescription from their provider and take it to the pharmacy to be filled.

6. If there is a medication not included, the member should consult their doctor for therapeutic alternatives first before submitting coverage exceptions to BCBSTX.

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member’s benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a MEDICAL POLICY and a member’s benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.

References:


Policy Update History:

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/23/2017</td>
<td>New policy, replaces medical policy ADM1001.030</td>
</tr>
<tr>
<td>07/14/2017</td>
<td>Removed codes 99174 and 99177.</td>
</tr>
<tr>
<td>12/06/2017</td>
<td>Coding and USPSTF updates</td>
</tr>
<tr>
<td>04/30/2018</td>
<td>Coding and USPSTF updates</td>
</tr>
<tr>
<td>07/12/2018</td>
<td>Coding and USPSTF updates</td>
</tr>
<tr>
<td>12/27/2018</td>
<td>Coding and USPSTF updates</td>
</tr>
<tr>
<td>09/26/2019</td>
<td>Coding and USPSTF updates</td>
</tr>
</tbody>
</table>

The Plan makes no endorsement, representations or warranties regarding any products or services offered by independent third-party vendors such as Babies ‘R’ Us, Target and Walmart. These vendors are solely responsible for the products and services they offer. If you have any questions about the products or services offered by such vendors, you should contact the vendor(s) directly.

By clicking this link, you will go to a new website/app (“site”). This new site may be offered by a vendor or an independent third party. The site may also contain non-Medicare related information. In addition, some sites may require you to agree to their terms of use and privacy policy.

File is in portable document format (PDF). To view this file, you may need to install a PDF reader program. Most PDF readers are a free download. One option is Adobe® Reader® which has a built-in screen reader. Other Adobe accessibility tools and information can be downloaded at http://access.adobe.com.

CPT copyright 2019 American Medical Association (AMA). All rights reserved. CPT is a registered trademark of the AMA.